California State Board of Pharmacy 2720 Gateway Oaks Drive, Suite 100 Sacramento, CA 95833 Phone: (916) 518-3100 Fax: (916) 574-8618 www.pharmacy.ca.gov



# Notice of Meeting and Agenda Teleconference Enforcement and Compounding Committee Meeting

Date &Time: July 18, 2023, 9:00 a.m.

Place: Department of Consumer Affairs 1625 N. Market Blvd, First Floor Hearing Room Sacramento, CA 95834

The Board is providing members of the public with different options to observe or participate in the meeting.

# FOR OBSERVATION AND PUBLIC COMMENT IN PERSON:

Department of Consumer Affairs 1625 N. Market Blvd, First Floor Hearing Room Sacramento, CA 95834

# FOR PUBLIC PARTICIPATION AND COMMENT FROM A REMOTE LOCATION, PLEASE LOG ON TO WEBEX:

To access the WebEx event, attendees will need to click the following link and enter a first name, last name, email, and the event password listed below: <u>https://dca-meetings.webex.com/dca-</u> <u>meetings/j.php?MTID=mb6da6d2ab31b9e5613fa88a065f58cbb</u>

<u>If joining using the link above</u> Webinar number: 2494 908 8328 Webinar password: CSBP07182023

<u>If joining by phone</u> +1-415-655-0001 US Toll Access code: 249 490 88328 Passcode: 27270718

Members of the public participating via WebEx will be able to hear the meeting and provide public comment but may not be able to observe the meeting. The preferred audio connection is via phone bridge. The phone number and access code will be provided as part of your connection to the meeting. General instructions for using WebEx can be found at the end of the agenda.

Members of the public may but are not obligated to provide their names or personal information as a condition of observing or participating in the meeting. When signing into the WebEx platform, participants may be asked for their name and email address. Participants who choose not to provide their names will need to provide a unique identifier such as their initials or another alternative, so that the meeting moderator can identify individuals who wish to make public comment; participants who choose not to provide their email address may utilize a fictitious email address in the following sample format: XXXX@mailinator.com.

## FOR OBSERVATION ONLY:

Livestream: The Committee plans to webcast this meeting on the Department of Consumer Affairs' website at <u>https://thedcapage.blog/webcasts</u>. Livestream will be available at the earliest at 9:00 a.m. July 18, 2023. Using the Livestream link will allow only for observation with closed captioning. Livestream availability cannot, however, be guaranteed due to resource limitations or technical difficulties. The meeting will not be cancelled if Webcast is unavailable. If you wish to participate, please plan to participate via the WebEx option listed above.

**Important Notices to the Public:** The Committee will hold a meeting in person that also includes participation by the public either in person at the public location identified on the first page of this agenda or via WebEx – access information is provided above. General instructions for using WebEx are attached to the agenda. The meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Debbie Damoth at (916) 518-3090, emailing Debbie.Damoth@dca.ca.gov, or sending a written request to the Board of Pharmacy, 2720 Gateway Oaks Drive, Suite 100, Sacramento CA 95833. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

The time and order of agenda items are subject to change at the discretion of the Committee Chair. In the event a quorum of the Committee is unable to attend the meeting, or the Committee is unable to maintain a quorum once the meeting is called to order, the members present may, at the Chair's discretion, continue to discuss items from the agenda and make recommendations to the full board at a future meeting.

Government Code section 11125.7 provides the opportunity for the public to address each agenda item during discussion or consideration by the Committee or prior to the Committee taking any action on said item. Members of the public will be provided appropriate opportunities to comment on any issues before the Committee, but the Chair may, at his or her discretion, apportion available time among those who wish to speak. If public comment is not specifically requested, members of the public should feel free to request an opportunity to comment. Individuals may appear before the Committee to discuss items not on the agenda; however, the Committee can neither discuss nor take official action on these items at the time of the same meeting (Government Code sections 11125, 11125.7(a)).

# <u>Agenda</u>

#### Discussion and action make be taken on any agenda item.

July 18, 2023

## Call to Order

## I. Call to Order, Establishment of Quorum, and General Announcements

- II. <u>Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings</u> Note: The Committee may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)]
- III. <u>Discussion, Consideration, and Approval of Draft Minutes from the April 13, 2023</u> <u>Enforcement and Compounding Committee Meeting</u>
- IV. Presentation on the Disciplinary Case Process by the Office of the Attorney General
- V. <u>Presentation and Discussion on Board's Inspection Program</u>
- VI. Presentation and Discussion on Board's Citation and Fine Program
- VII. <u>Presentation and Discussion on Quality Assurance Reports Received Pursuant to</u> <u>California Code of Regulations section 1711(f) related to the Use of Automated Drug</u> <u>Delivery Systems</u>
- VIII. <u>Discussion and Consideration of Draft Proposed Policy Statement Related to</u> <u>Implementation of USP General Chapters 795 Pharmaceutical Compounding –</u> <u>Nonsterile Preparations; 797 Pharmaceutical Compounding – Sterile Preparations; 800</u> <u>Hazardous Drugs – Handling in Healthcare Settings; and 825 Radiopharmaceuticals –</u> <u>Preparation, Compounding, Dispensing, and Repackaging</u>
- IX. Discussion and Consideration of Committee's Strategic Objectives
- X. Discussion and Consideration of Enforcement Statistics
- XI. <u>Future Committee Meeting Dates</u>
- XII. Adjournment

Upon conclusion of business